Endocrine Abstracts (2007) 14 P656

Reproductive health of women born to bromocriptine-treated mothers

Evgenia Rashidova, Valentina Kokolina, Tatiana Romantsova & Alexej Bobrov

Moscow Medical Academy, Moscow, Russia.

A retrospective cohort study was undertaken using a reproductive health survey of 25 girls aged 14–27 years (Me 20,5 (16;23)) born to bromocriptine-treated mothers. The control group consisted of 25 women born after spontaneous pregnancy of the same age, mother age, region of residence. They were all seen in the clinic for health and psychological interviews (Multiscale Personality Assessment Test- MMPI). All of them were blood analysed for LG, FSG, prolactin, TSH, anti-TPO, testosterone and DHEAS levels; ultrasonography of the mammary gland, internal genitalia with calculation of ovarian volume was presented. Pearson Chi-Square and Fisher’s Exact test were used for comparing results in two groups. No difference between two groups (P>0,05) was found in hormonal levels, the incidence of menstrual cycle disorders and gynaecological desease, all women had normally developed internal and external genitalia. One of them has prolactin-secreting microadenoma, receives parlodel. Women born to bromocriptine-treated mothers had earlier menarche (Me 12 (12;13)) comparing to control group (Me 13 (12;14))(P=0.046). We found a high frequency of primary hypothyroidism in women born to bromocriptine-treated mothers -20% (5 women- 3 with subclinical and 2 with overt). The early age of manifestation (9 to 18 years) and absence of anti- thyroid antibodies are their remarkable features. Different pscopatological syndroms and psychosomatic disorders were found in 9 from 16 women (62.5%) who underwent psicological testing using MMPI compairing to 3 from 18 (16.6%) in control group (P=0.015) 8 women born to bromocriptine-treated mothers had spontaneous pregnancies and 7 of them have healthy children. 6 were born in term, one child was born pretermed because of intrauterine infection. The study provides additional evidence that in utero exposure to bromocriptine doesn’t have severe adverse effects on later health outcomes including reproductive function. The prevalence of psycopatological syndromes may be due to specific family education.

Article tools

My recent searches

No recent searches.